严格;肖军;张赟;王健;李郅涵;张洋;史占军;

• 1:南方医科大学附属南方医院关节与骨病外科

摘要(Abstract)：

[目的]对比利伐沙班和那曲肝素对人工膝关节表面置换术(TKA)术后失血量的影响。[方法]接受初次单侧TKA手术的骨性关节炎患者79例,随机分为利伐沙班组(n=53)和那曲肝素组(n=26)。记录术后切口总引流量、自体血回输量和异体血输血量。测量术前及术后1、3、5 d血常规,通过Gross方程计算TKA术后隐性失血量和总失血量。[结果]利伐沙班组总引流量、回输量分别为(784.34±367.78)ml,(561.89±305.86)ml,与那曲肝素组相当[引流量和回输量分别为(713.46±356.94)ml和(479.62±259.85)ml,P=0.42和0.24]。术后5 d利伐沙班组Hb为(90.68±11.89)g/L,显著低于那曲肝素组(98.77±12.01 g/L,P=0.01)。两种抗凝药的应用对于患者术前、术后1、3、5 d的Hb及Hct总体的影响均不具备组间统计学差异(P>0.05)。隐性失血量、总失血量分别为(1 361.46±601.01)ml,(2 207.40±651.95)ml,与那曲肝素组相当[隐性失血量、总失血量分别为(1135.01±755.35)ml,(1 917.09±811.30)ml;P=0.15,P=0.09]。异体血输注率54.72%,输血量(307.55±329.25)ml,与那曲肝素组均无组间显著性差异(异体血输血率38.46%,输血量[(230.77±323.44)ml,P=0.17和P=0.28)]。[结论]相对于那曲肝素,利伐沙班并不增加术后失血量和异体血输血率。

关键词(KeyWords)： 膝关节表面置换术;利伐沙班;那曲肝素;失血量

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(编号:81101389);; 广东省自然科学基金资助项目(编号:S2011040003467)

作者(Author): 严格;肖军;张赟;王健;李郅涵;张洋;史占军;

Email:

DOI:

参考文献(References)：

• [1]Imberti D,Gallerani M,Manfredini R.Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery[J].J Thromb Thrombolysis,2012,2:208-213.
• [2]Kanchanabat B,Stapanavatr W,Meknavin S,et al.Systematic review and meta-analysis on the rate of postoperative venous thromboembolism in orthopaedic surgery in Asian patients without thromboprophylaxis[J].Br J Surg,2011,10:1356-1364.
• [3]Green L,Lawrie AS,Patel R,et al.The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters[J].Thromb Res,2012,5:775-779.
• [4]Turpie AG,Schmidt AC,Kreutz R,et al.Rationale and design of XAMOS:noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery[J].Vasc Health Risk Manag,2012,8:363-370.
• [5]Cho KY,Kim KI,Khurana S,et al.Is routine chemoprophylaxis necessary for prevention of venous thromboembolism following knee arthroplasty in a low incidence population[J].Arch Orthop Trauma Surg,2013,4:551-559.
• [6]Mismetti P,Laporte S,Darmon JY,et al.Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery[J].Br J Surg,2001,7:913-930.
• [7]李军,朱天岳,马忠泰,等.低分子肝素预防髋关节置换术后深静脉血栓的安全性[J].中国矫形外科杂志,2004,16:1223-1225.
• [8]Turpie AG,Bauer KA,Eriksson BI,et al.Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery:a meta-analysis of 4 randomized double-blind studies[J].Arch Intern Med,2002,16:1833-1840.
• [9]Intermountain Joint Replacement Center Writing C.A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty[J].J Arthroplasty,2012,1:1-9.
• [10]Reynolds NA,Perry CM,Scott LJ.Fondaparinux sodium:a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery[J].Drugs,2004,14:1575-1596.
• [11]Eriksson BI,Borris LC,Friedman RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,26:2765-2775.
• [12]Lassen MR,Ageno W,Borris LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,26:2776-2786.
• [13]Rath NK,Goodson MW,White SP,et al.The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement[J].Knee,2013,6:397-400.
• [14]Jameson SS,Rymaszewska M,Hui AC,et al.Wound complications following rivaroxaban administration:a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty[J].J Bone Joint Surg Am,2012,17:1554-1558.
• [15]Sindali K,Rose B,Soueid H,et al.Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing[J].Eur J Orthop Surg Traumatol,2013,4:481-486.